Printer Friendly

DISEASE DETECTION INTERNATIONAL INC. (DDI) ANNOUNCES BRASILIAN APPROVAL TO SELL RAPID, ON-SITE, AIDS TEST

 DDI Forms Manufacturing and Distribution Joint Venture in Brasil
 IRVINE, Calif., June 30 /PRNewswire/ -- Disease Detection International Inc. (OTC Bulletin Board: DDII) (DDI) recently received preliminary approval and specific recommendation from the state of Sao Paulo, Brasil to sell its SeroCard(R) HIV-1, rapid (seven-minute) whole-blood, AIDS test. In studies performed at the Adolpho Lutz Institute in Sao Paulo, the SeroCard HIV-1 test was found "suitable for use as a screening test to detect the presence of antibodies to the AIDS virus." Additional studies performed within the state prison system generated similar enthusiasm for DDI's patented format which utilizes whole blood from a simple prick of the finger to perform the world's first "whole-blood ELISA test in under eight minutes."
 DDI's President and Chief Executive Officer, H. Thad Morris stated "This enthusiastic endorsement was particularly significant in light of the fact that the state of Sao Paulo, with a population of more than 33 million people, has more than three times the rate of infection than the nation of 150 million people as a whole." Morris went on to announce the formation of a Brasilian joint venture established by DDI for the manufacture and sale of the company's family of rapid diagnostic products. The company expects to receive national registration within the next few months.
 The Brasilian joint venture will be named Disease Detection International do Brasil ("DDI do Brasil") and will be managed by Joao Carlos S. Bento, a Brasilian businessman who has been working with the company and Brasilian health authorities to obtain approval of DDI's SeroCard HIV-1, rapid (seven-minute), whole-blood AIDS test. Bento, along with several Sao Paulo physicians and business associates, will own 51 percent of the joint venture and the company will own 49 percent. As a majority-owned, Brasilian company, DDI do Brasil will enjoy certain local incentives and commercial benefits.
 Bento commented, "Our local health authorities are very enthusiastic over the performance of the SeroCard HIV-1 test in several studies in the private sector, prison systems and more recently, from studies performed by the infectious disease testing labs in one of our most prestigious university laboratories conducting research for infectious diseases. The possibility of having such a rapid and convenient test available within our health care system will be a true asset for our state and country, where recent studies report up to 30 percent of donated blood may go untested for AIDS due to the lack of sophisticated, expensive instrumentation and highly trained personnel in satellite regions. The SeroCard HIV-1 test requires no instrumentation and can be performed in minutes utilizing existing staff."
 Morris further commented, "The establishment of a Brasilian company will provide local support and manufacturing in addition to collaborations with state and national health authorities to provide education and counseling to the general population. DDI believes the pandemic can only be slowed by providing all these tools along with the personal knowledge of one's own HIV status. We are seeking to establish similar subsidiaries or joint ventures in Argentina, Colombia, Venezuela and Bolivia during the remainder of 1993."
 Disease Detection International Inc. develops manufactures and markets a family of whole blood and saliva-based rapid diagnostic tests for infectious and sexually transmitted diseases in addition to rapid diagnostic tests for pregnancy, which are sold to physicians, hospitals, laboratories and consumers.
 -0- 6/30/93
 /CONTACT: H. Thad Morris, president and CEO of Disease Detection International, 714-457-1787/
 (DDII)


CO: Disease Detection International Inc. ST: California IN: MTC SU: CON

EH -- LA017 -- 7086 06/30/93 10:58 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1993
Words:586
Previous Article:ROBERTSON STEPHENS INTRODUCES NEW CONTRARIAN MUTUAL FUND
Next Article:PRUDENTIAL HOME MORTGAGE CLOSES $1.1 BILLION UNSECURED WAREHOUSE LINE
Topics:


Related Articles
DISEASE DETECTION INTERNATIONAL FORMS NEW WOMEN'S HEALTH CARE COMPANY FOR O.T.C., RETAIL SALES OF PHARMACEUTICALS AND RAPID PREGNANCY TESTS
DISEASE DETECTION INTERNATIONAL REPORTS RECORD REVENUES AND PROFITS FOR FISCAL 1992 AND SIGNIFICANT FORECASTS FOR 1993 AND BEYOND
DISEASE DETECTION INTERNATIONAL INC. SIGNS DISTRIBUTION AGREEMENTS WITH BAXTER'S SCIENTIFIC PRODUCTS DIVISION FOR ONE-STEP PREGNANCY TEST
DISEASE DETECTION INTERNATIONAL, INC., SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT FOR SEVEN-MINUTE AIDS TEST FOR ARGENTINA
DISEASE DETECTION INTERNATIONAL COMPLETES $8.7M THREE-COUNTRY, THREE- YEAR DISTRIBUTION AGREEMENTS FOR SALE OF RAPID AIDS TEST KITS IN S.A.
TRINITY BIOTECH PLC REPORTS YEAR END RESULTS
TRINITY BIOTECH PLC COMPLETES MERGER WITH DISEASE DETECTION INTERNATIONAL AND CHANGES NASDAQ TICKER SYMBOL
TRINITY BIOTECH PLC REPORTS 6 MONTH FINANCIAL RESULTS
TRINITY BIOTECH ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT FOR DDI MERGER
INTERNATIONAL MUREX TECHNOLOGIES EXPANDS INTO $20 MILLION U.S. MARKET

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters